Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Turn Therapeutics Inc.TTRX · Entity 5935 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Turn Therapeutics Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2036-06-04 | Direct | 83,334 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 83,334 · Balance 83,334 F1: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 21:30 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantStock option (right to buy) · Derivative | 83,334 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001213900-26-066391 · ownership.xml · derivative · entry 1 Kester Kent Edward · CIK 0002087469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 83,334 shares Expires 2036-06-04 F1 · derivative.exercise_date: The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 13:42 UTC | Turn Therapeutics Inc. TTRX · Entity 5935 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-098570 · tm2528487-4_4seq1.xml · nonDerivative · entry 1 Kester Kent Edward · CIK 0002087469 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · security: Reflects an award of restricted stock units ("RSUs") granted under the Issuer's 2025 Omnibus Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs will vest upon the earlier of the first anniversary of the grant date or a change in control of the Issuer, in each case, subject to the reporting person's continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.